<![CDATA[Galderma 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=21628>Sat, 14 Mar 2026 02:03:23 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering]]>https://www.newswire.co.kr/newsRead.php?no=1030105Wed, 11 Mar 2026 15:53:00 +0900<![CDATA[Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin]]>https://www.newswire.co.kr/newsRead.php?no=1029955Tue, 10 Mar 2026 09:43:41 +0900<![CDATA[Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years]]>https://www.newswire.co.kr/newsRead.php?no=1029424Fri, 27 Feb 2026 15:39:55 +0900<![CDATA[Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics]]>https://www.newswire.co.kr/newsRead.php?no=1029211Wed, 25 Feb 2026 15:58:43 +0900<![CDATA[Galderma Announces Appointment of New Chief Financial Officer]]>https://www.newswire.co.kr/newsRead.php?no=1028845Wed, 18 Feb 2026 09:09:15 +0900<![CDATA[We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties]]>https://www.newswire.co.kr/newsRead.php?no=1028710Thu, 12 Feb 2026 15:22:22 +0900<![CDATA[Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™]]>https://www.newswire.co.kr/newsRead.php?no=1028603Wed, 11 Feb 2026 15:13:58 +0900<![CDATA[Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission]]>https://www.newswire.co.kr/newsRead.php?no=1028020Mon, 02 Feb 2026 15:13:57 +0900<![CDATA[Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity]]>https://www.newswire.co.kr/newsRead.php?no=1027937Fri, 30 Jan 2026 15:34:49 +0900<![CDATA[Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty]]>https://www.newswire.co.kr/newsRead.php?no=1027831Thu, 29 Jan 2026 15:24:15 +0900<![CDATA[IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio]]>https://www.newswire.co.kr/newsRead.php?no=1027396Thu, 22 Jan 2026 15:41:36 +0900<![CDATA[Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership]]>https://www.newswire.co.kr/newsRead.php?no=1027347Thu, 22 Jan 2026 09:16:59 +0900<![CDATA[TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics]]>https://www.newswire.co.kr/newsRead.php?no=1026939Wed, 14 Jan 2026 16:32:51 +0900<![CDATA[New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis]]>https://www.newswire.co.kr/newsRead.php?no=1025566Wed, 17 Dec 2025 15:45:55 +0900<![CDATA[Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin]]>https://www.newswire.co.kr/newsRead.php?no=1025162Thu, 11 Dec 2025 16:35:51 +0900<![CDATA[Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body]]>https://www.newswire.co.kr/newsRead.php?no=1024737Fri, 05 Dec 2025 15:40:00 +0900<![CDATA[Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings]]>https://www.newswire.co.kr/newsRead.php?no=1024624Thu, 04 Dec 2025 15:09:04 +0900<![CDATA[ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline]]>https://www.newswire.co.kr/newsRead.php?no=1023211Mon, 17 Nov 2025 15:50:00 +0900<![CDATA[AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education]]>https://www.newswire.co.kr/newsRead.php?no=1019432Wed, 24 Sep 2025 16:10:00 +0900<![CDATA[Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay]]>https://www.newswire.co.kr/newsRead.php?no=1019051Thu, 18 Sep 2025 15:34:34 +0900<![CDATA[Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin]]>https://www.newswire.co.kr/newsRead.php?no=1018946Wed, 17 Sep 2025 16:10:00 +0900<![CDATA[EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch]]>https://www.newswire.co.kr/newsRead.php?no=1018568Thu, 11 Sep 2025 15:50:00 +0900<![CDATA[Galderma Launches Alastin® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market]]>https://www.newswire.co.kr/newsRead.php?no=1018487Wed, 10 Sep 2025 16:30:00 +0900<![CDATA[Galderma Delivers Record First Half 2025 Net Sales of 2.448 Billion USD and 12.2% Year-on-Year Growth at Constant Currency, Raises Full-Year Top-Line Guidance]]>https://www.newswire.co.kr/newsRead.php?no=1015543Thu, 24 Jul 2025 14:52:18 +0900<![CDATA[Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss]]>https://www.newswire.co.kr/newsRead.php?no=1015137Thu, 17 Jul 2025 14:23:23 +0900